Revisiting the optimal neoadjuvant immunotherapy regimen in resectable stage III melanoma based on the interferon gamma signature: A pooled analysis.
Minke W. Lucas, Petros Dimitriadis, Irene L. M. Reijers, Alexander M. Menzies, Elisa A. Rozeman, Judith M. Versluis, Alexander C. Huang, Sten Cornelissen, Annegien Broeks, Richard A Scolyer, Tara C. Mitchell, Georgina V. Long, Christian U. Blank (2023). Revisiting the optimal neoadjuvant immunotherapy regimen in resectable stage III melanoma based on the interferon gamma signature: A pooled analysis.. , 41(16_suppl), DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.9516.
